Loading...
Docoh
Log in Free sign up

Tenax Therapeutics (TENX)

News

From Benzinga Pro
Tenax Therapeutics Announces $8M PIPE Offering Priced At-The-Market under Nasdaq Rules
18 May 22
News, Financing
Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need,
TENX: 2021 Financial and Operational Review
1 Apr 22
Penny Stocks
By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT
12 Health Care Stocks Moving In Monday's After-Market Session
14 Mar 22
Movers
Gainers Sigilon Therapeutics (NASDAQ:SGTX) stock rose 15.5% to $1.49 during Monday's after-market session. The market value of their outstanding shares is at $48.1 million.
Stocks That Hit 52-Week Lows On Tuesday
8 Mar 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
Tuesday's session saw 729 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Monday
28 Feb 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Monday morning, 66 companies achieved new lows for the year.

Press releases

From Benzinga Pro
Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq Rules
18 May 22
Press Releases
Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need,
Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update
31 Mar 22
Press Releases
Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need,
Tenax Therapeutics Announces Two Presentations at Upcoming American College of Cardiology Scientific Sessions
30 Mar 22
Press Releases
Presentations Will Feature the Company's Two Late-Stage Drug Candidates: Imatinib for Treatment of Pulmonary Arterial Hypertension (PAH) and Levosimendan for Treatment of Pulmonary Hypertension Associated with Left